1. LncRNA GHET1 from bone mesenchymal stem cell–derived exosomes improves doxorubicin-induced pyroptosis of cardiomyocytes by mediating NLRP3
- Author
-
Xiaoya Zhai, Jiedong Zhou, Xingxiao Huang, Jingfan Weng, Hui Lin, Shimin Sun, Jufang Chi, and Liping Meng
- Subjects
Doxorubicin ,Cardiotoxicity ,Pyroptosis ,Bone mesenchymal stem cell ,Exosome ,Medicine ,Science - Abstract
Abstract Doxorubicin (DOX) is an important chemotherapeutic agent for the treatment of hematologic tumors and breast carcinoma. However, its clinical application is limited owing to severe cardiotoxicity. Pyroptosis is a form of programmed cell death linked to DOX-induced cardiotoxicity. Bone mesenchymal stem cell–derived exosomes (BMSC-Exos) and endothelial progenitor cells-derived exosomes (EPC-Exos) have a protective role in the myocardium. Here we found that BMSC-Exos could improve DOX-induced cardiotoxicity by inhibiting pyroptosis, but EPC-Exos couldn’t. Compared with EPCs-Exo, BMSC-Exo-overexpressing lncRNA GHET1 more effectively suppressed pyroptosis, protecting against DOX-induced cardiotoxicity. Further studies showed that lncRNA GHET1 effectively decreased the expression of Nod-like receptor protein 3 (NLRP3), which plays a vital role in pyroptosis by binding to IGF2 mRNA-binding protein 1 (IGF2BP1), a non-catalytic posttranscriptional enhancer of NLRP3 mRNA. In summary, lncRNA GHET1 released by BMSC-Exo ameliorated DOX-induced pyroptosis by targeting IGF2BP1 to reduce posttranscriptional stabilization of NLRP3.
- Published
- 2024
- Full Text
- View/download PDF